BioNovix

BioNovix is a clinical-stage biotechnology company based in San Diego, California, specializing in the development of oral small-molecule therapeutics for viral and inflammatory diseases. The company's lead candidate, BNX-101, is a broad-spectrum antiviral agent designed to inhibit the viral RNA-dependent RNA polymerase (RdRp). BNX-101 has been evaluated for the treatment of influenza and has demonstrated potential against a variety of viral strains, including those resistant to existing therapies. In addition to its work in influenza, BioNovix has explored the application of its antiviral candidates for the treatment of COVID-19 and other respiratory viral infections. The company leverages collaborations with leading research institutions, such as Scripps Research, to advance its drug discovery and development efforts. BioNovix aims to address significant unmet needs in the management of seasonal and pandemic viral threats through the development of effective and accessible oral medications.